Research programme: therapeutic agents - KineMed/Bayer
Latest Information Update: 23 Mar 2011
At a glance
- Originator Bayer HealthCare; KineMed
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 29 Mar 2010 Preclinical development is ongoing in USA
- 06 Feb 2007 Preclinical trials in Undefined in USA (unspecified route)